Study to Assess the Safety and Tolerability of Tafasitamab in Adult Participants With Primary Autoimmune Blood Cell Disorders
Clinical trial NCT07104565 · RECRUITING
Trial details
- NCT number
- NCT07104565
- Sponsor
- Incyte Corporation
- Status
- RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2025-12-29
- Primary completion
- 2027-09-23
- Enrollment
- 56
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.